HK1202157A1 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment - Google Patents

Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Info

Publication number
HK1202157A1
HK1202157A1 HK15102644.9A HK15102644A HK1202157A1 HK 1202157 A1 HK1202157 A1 HK 1202157A1 HK 15102644 A HK15102644 A HK 15102644A HK 1202157 A1 HK1202157 A1 HK 1202157A1
Authority
HK
Hong Kong
Prior art keywords
prediction
coronary artery
artery disease
disease patients
statin treatment
Prior art date
Application number
HK15102644.9A
Other languages
English (en)
Chinese (zh)
Inventor
Reijo Laaksonen
Kim Ekroos
Reini Hurme
Minna Jnis
Riikka Katainen
Kirill Tarasov
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of HK1202157A1 publication Critical patent/HK1202157A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
HK15102644.9A 2011-11-08 2015-03-16 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment HK1202157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556909P 2011-11-08 2011-11-08
EP11188328.6A EP2592423A1 (en) 2011-11-08 2011-11-08 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
PCT/EP2012/071972 WO2013068373A2 (en) 2011-11-08 2012-11-07 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Publications (1)

Publication Number Publication Date
HK1202157A1 true HK1202157A1 (en) 2015-09-18

Family

ID=45033777

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102644.9A HK1202157A1 (en) 2011-11-08 2015-03-16 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Country Status (7)

Country Link
US (3) US9052328B2 (xx)
EP (3) EP2592423A1 (xx)
JP (1) JP6388283B2 (xx)
CN (1) CN103917876B (xx)
CA (1) CA2853220A1 (xx)
HK (1) HK1202157A1 (xx)
WO (1) WO2013068373A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
ES2552371T3 (es) * 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)
CA2926592A1 (en) * 2013-11-14 2015-05-21 Nestec S.A. Lipid biomarkers of healthy ageing
CN106457090B (zh) 2014-04-10 2020-09-29 Mep马解决方案有限责任公司 粪便中寄生虫卵的定量方法
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
WO2016100549A2 (en) 2014-12-16 2016-06-23 Washington University Ceramides for evaluating risk of cardiovascular disease
US20180238914A1 (en) * 2015-08-19 2018-08-23 Metanomics Gmbh Means and methods for diagnosing cardiac disease in a subject
US20180306821A1 (en) * 2015-10-20 2018-10-25 Medimmune, Llc Diagnostic marker for coronary artery disease
US10184932B2 (en) 2015-12-07 2019-01-22 Zora Biosciences Oy Use of ceramides and LPLs in diagnosing CVD
CN105424841B (zh) * 2015-12-25 2017-11-03 齐炼文 用于诊断冠状动脉粥样硬化的代谢标志物
CN107014942A (zh) * 2017-05-05 2017-08-04 北京骐骥生物技术有限公司 利用脂质生物标志物预测糖尿病冠心病的方法
CN107144624B (zh) * 2017-05-15 2021-01-05 中国科学院生态环境研究中心 甄别二氧化硅颗粒来源的方法
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
SG11202105172PA (en) 2018-12-06 2021-06-29 Zora Biosciences Oy Biomarkers for cardiovascular events
CN113533754A (zh) * 2021-07-12 2021-10-22 北京市心肺血管疾病研究所 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7590198A (en) * 1997-06-10 1998-12-30 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
WO2004038381A2 (en) 2002-10-25 2004-05-06 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
DE102006034153B4 (de) 2006-07-24 2018-02-08 Magna powertrain gmbh & co kg Getriebe
US20100179066A1 (en) 2007-06-07 2010-07-15 Inserm (Institut National De La Santé Et De La Rec Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia
CN105548585B (zh) * 2007-06-08 2018-12-28 奎斯特诊断投资公司 通过差分带电荷微粒迁移率进行脂蛋白分析
EP2048243A1 (en) 2007-09-24 2009-04-15 sanofi-aventis Use of clec1B for the determination of cardiovascular and thrombotic risk
EP2247775B1 (en) 2008-01-28 2012-12-19 National University of Singapore Method of generating a classification model
US8507209B2 (en) 2008-03-12 2013-08-13 Otago Innovation Limited Biomarkers
RU2545757C2 (ru) 2008-10-30 2015-04-10 Сантр Де Решерш Пюблик Де Ля Сантэ Биомаркеры
US20110034419A1 (en) * 2009-06-27 2011-02-10 Musc Foundation For Research Development Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease
JP5739898B2 (ja) * 2009-11-17 2015-06-24 ベイラー リサーチ インスティテュートBaylor Research Institute 心疾患マーカーとしての尿中トリアオシルセラミド(gb3)
WO2011063470A1 (en) 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
US9201080B2 (en) 2010-06-20 2015-12-01 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
JP5980900B2 (ja) 2011-04-08 2016-08-31 ゾラ バイオサイエンシーズ オサケ ユキチュア スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment

Also Published As

Publication number Publication date
EP2592423A1 (en) 2013-05-15
US20140295467A1 (en) 2014-10-02
CN103917876B (zh) 2018-02-02
CA2853220A1 (en) 2013-05-16
US20150260737A1 (en) 2015-09-17
EP2776841B1 (en) 2017-01-11
EP3208617A3 (en) 2017-11-01
WO2013068373A3 (en) 2013-07-18
US20160320418A1 (en) 2016-11-03
WO2013068373A2 (en) 2013-05-16
US9052328B2 (en) 2015-06-09
JP6388283B2 (ja) 2018-09-12
EP3208617B1 (en) 2021-02-24
CN103917876A (zh) 2014-07-09
US9423406B2 (en) 2016-08-23
JP2014532885A (ja) 2014-12-08
EP2776841A2 (en) 2014-09-17
EP3208617A2 (en) 2017-08-23
US9863965B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
HK1202154A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
HK1202157A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
SI2619576T1 (sl) Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
EP2686446A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR MACULOPATHY AND SYMPTOMS THEREOF
HK1198556A1 (en) Prediction of outcome in patients with chronic obstructive pulmonary disease
EP2529033A4 (en) METHOD AND COMPOSITIONS FOR RISK OVERVIEW, DIAGNOSIS, FORECASTING AND TREATMENT OF LUNG DISEASES
SMT201600235B (it) Predittori per il trattamento del cancro
EP2668504A4 (en) PREDICTIVE TEST FOR SELECTING PATIENTS WITH METASTATIC BREAST CANCERS TO RECEIVE HORMONE THERAPY AND POLY THERAPY
EP2723866A4 (en) METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES
SG11201400919RA (en) Patient stratification and determining clinical outcome for cancer patients
IL222844A0 (en) Biomarkers for the treatment of psoriasis
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
IL223310A0 (en) Apple skin extracts for treating cardiovascular disease
EP2709618A4 (en) METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
EP2557920A4 (en) METHODS FOR THE TREATMENT OF GLUCOSE METABOLISM DISORDERS
ZA201307905B (en) Use of fk506 for the treatment of pulmonary arterial hypertension
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
PT2807486T (pt) Método para a previsão in vitro, numa amostra sanguínea, da probabilidade de um paciente desenvolver dengue grave
GB201101959D0 (en) Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
EP2755671A4 (en) COMBINATION OF PTEROSTILS AND STATINE FOR THE TREATMENT OF METABOLISM DISEASES, CARDIOVASCULAR DISEASES AND INFLAMMATION
IL228891A (en) 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease
EP2528612A4 (en) METHODS OF TREATING GLUCOSE METABOLISM DISORDERS
GB201218050D0 (en) Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome
EP2523730A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
EP2820426A4 (en) NOVEL TARGET MOLECULE FOR THE DIAGNOSIS AND TREATMENT OF DIABETES AND HEART CIRCULAR DISEASES